These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 8722344

  • 1. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K, Clift R, Fefer A, Storb R, Slattery JT.
    Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
    [Abstract] [Full Text] [Related]

  • 2. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb R, Slattery JT.
    Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
    [Abstract] [Full Text] [Related]

  • 3. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB, Buckner CD, Appelbaum FR, Clift RA, Sanders JE, Bensinger WI, Storb R, Witherspoon RP, Sullivan KM, Bearman SI.
    Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
    [Abstract] [Full Text] [Related]

  • 4. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.
    McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):853-62. PubMed ID: 17580264
    [Abstract] [Full Text] [Related]

  • 5. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.
    Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, Norstad D, Cowan MJ.
    Bone Marrow Transplant; 2001 Dec; 28(11):1013-8. PubMed ID: 11781609
    [Abstract] [Full Text] [Related]

  • 6. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fefer A, Rowley S, Sanders J, Chauncey T, Storb R, Lilleby K, Buckner CD.
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [Abstract] [Full Text] [Related]

  • 7. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.
    J Clin Oncol; 2013 Oct 01; 31(28):3549-56. PubMed ID: 23980086
    [Abstract] [Full Text] [Related]

  • 11. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N.
    Bone Marrow Transplant; 1998 Jun 01; 21(11):1079-83. PubMed ID: 9645568
    [Abstract] [Full Text] [Related]

  • 12. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
    Socié G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ, Remberger M, Deeg HJ, Ruutu T, Michallet M, Sullivan KM, Chevret S.
    Blood; 2001 Dec 15; 98(13):3569-74. PubMed ID: 11739158
    [Abstract] [Full Text] [Related]

  • 13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May 15; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 14. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
    Michel G, Socié G, Gebhard F, Bernaudin F, Thuret I, Vannier JP, Demeocq F, Leverger G, Pico JL, Rubie H, Mechinaud F, Reiffers J, Gratecos N, Troussard X, Jouet JP, Simonin G, Gluckman E, Maraninchi D.
    J Clin Oncol; 1997 Jun 15; 15(6):2238-46. PubMed ID: 9196136
    [Abstract] [Full Text] [Related]

  • 15. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
    Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, Bordigoni P, Ifrah N, Dauriac C, Cahn JY.
    Blood; 1995 Apr 15; 85(8):2263-8. PubMed ID: 7718899
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
    Hartsell WF, Czyzewski EA, Ghalie R, Kaizer H.
    Int J Radiat Oncol Biol Phys; 1995 Apr 30; 32(1):69-73. PubMed ID: 7536723
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.